Isomorphic Labs In Talks At $40B

Alphabet's AI drug discovery unit Isomorphic Labs, led by Demis Hassabis, is reportedly in funding talks at a $40 billion valuation. The round would give the company fresh capital to accelerate its AI-driven drug development push amid surging investor appetite for AI despite bubble concerns.

3 effects · 1 potentially affected company · The full cascade analysis is part of the Pro plan. Create free account

A $40 billion valuation for Isomorphic Labs would mark one of the largest private valuations in AI-driven biotech, underscoring investor conviction that AI can materially speed drug discovery. Fresh capital would let the Alphabet-backed unit expand its pipeline of AI-designed therapeutic candidates and pursue more pharma partnerships. The raise also reinforces Alphabet's strategic position in AI drug discovery without requiring direct balance-sheet exposure. It adds to a wave of mega-valuations across AI labs (OpenAI, DeepSeek, Moonshot) that is fueling bubble concerns among market watchers. If completed, it could pressure rival AI drug discovery platforms to raise larger rounds to stay competitive for talent and partnerships.